Total Payments
$610,618
2024 Payments
$193,788
Companies
33
Transactions
587
Medicare Patients
613
Medicare Billing
$103,139
Payment Breakdown by Category
Consulting$233,565 (38.3%)
Other$231,313 (37.9%)
Travel$112,117 (18.4%)
Food & Beverage$17,905 (2.9%)
Research$15,000 (2.5%)
Education$717.68 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $233,565 | 70 | 38.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $194,610 | 56 | 31.9% |
| Travel and Lodging | $112,117 | 164 | 18.4% |
| Honoraria | $36,630 | 12 | 6.0% |
| Food and Beverage | $17,905 | 260 | 2.9% |
| Unspecified | $15,000 | 14 | 2.5% |
| Education | $717.68 | 10 | 0.1% |
| Entertainment | $72.73 | 1 | 0.0% |
Payments by Type
General
$595,618
573 transactions
Research
$15,000
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $219,348 | 107 | $0 (2024) |
| Astellas Pharma US Inc | $70,950 | 64 | $0 (2024) |
| Merck Sharp & Dohme LLC | $63,610 | 47 | $0 (2024) |
| Exelixis Inc. | $42,147 | 48 | $0 (2024) |
| GENZYME CORPORATION | $41,092 | 28 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $38,487 | 57 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $32,008 | 36 | $0 (2024) |
| EMD Serono, Inc. | $29,550 | 26 | $0 (2023) |
| Telix Pharmaceuticals | $15,543 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $13,417 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $193,788 | 160 | PFIZER INC. ($75,363) |
| 2023 | $201,037 | 145 | PFIZER INC. ($98,088) |
| 2022 | $90,236 | 107 | GENZYME CORPORATION ($21,664) |
| 2021 | $39,778 | 27 | Astellas Pharma US Inc ($9,750) |
| 2020 | $45,579 | 51 | Astellas Pharma US Inc ($14,001) |
| 2019 | $38,768 | 83 | PFIZER INC. ($11,992) |
| 2018 | $1,362 | 13 | Astellas Pharma US Inc ($750.00) |
| 2017 | $70.04 | 1 | Genentech USA, Inc. ($70.04) |
All Payment Transactions
587 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $1,120.03 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $663.21 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $31.17 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $1,348.79 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $157.50 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $603.20 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $358.67 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $191.88 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $124.76 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $40.02 | General |
| Category: Oncology | ||||||
| 11/09/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $723.26 | General |
| 11/09/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $161.93 | General |
| 11/08/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, ORGOVYX | Food and Beverage | In-kind items and services | $50.14 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $145.83 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/07/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 10/28/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,555.00 | General |
| 10/28/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Travel and Lodging | In-kind items and services | $123.48 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $100.21 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $15,000 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 169 | 256 | $53,010 | $23,613 |
| 2022 | 3 | 100 | 207 | $54,511 | $14,836 |
| 2021 | 4 | 139 | 365 | $109,431 | $30,720 |
| 2020 | 6 | 205 | 509 | $111,782 | $33,971 |
Total Patients
613
Total Services
1,337
Medicare Billing
$103,139
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 52 | $12,376 | $5,741 | 46.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 39 | $9,282 | $4,287 | 46.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 41 | $8,774 | $3,845 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 40 | $6,320 | $2,987 | 47.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 37 | $5,846 | $2,757 | 47.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $4,556 | $1,783 | 39.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 17 | 17 | $4,556 | $1,573 | 34.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 13 | $1,300 | $641.05 | 49.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 159 | $43,939 | $11,946 | 27.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 22 | 37 | $6,940 | $1,685 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 11 | 11 | $3,632 | $1,205 | 33.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 266 | $73,980 | $20,649 | 27.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 23 | 60 | $24,332 | $7,029 | 28.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 19 | 19 | $7,319 | $1,977 | 27.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 14 | 20 | $3,800 | $1,065 | 28.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 99 | 343 | $69,536 | $20,889 | 30.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 74 | $21,016 | $6,841 | 32.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 20 | 20 | $6,785 | $2,052 | 30.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 23 | $6,118 | $1,926 | 31.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 23 | 29 | $4,647 | $1,223 | 26.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 20 | $3,680 | $1,039 | 28.2% |
About Dr. Pedro Barata, M.D
Dr. Pedro Barata, M.D is a Hematology & Oncology healthcare provider based in New Orleans, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2016. The National Provider Identifier (NPI) number assigned to this provider is 1841746542.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pedro Barata, M.D has received a total of $610,618 in payments from pharmaceutical and medical device companies, with $193,788 received in 2024. These payments were reported across 587 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($233,565).
As a Medicare-enrolled provider, Barata has provided services to 613 Medicare beneficiaries, totaling 1,337 services with total Medicare billing of $103,139. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New Orleans, LA
- Active Since 09/01/2016
- Last Updated 05/20/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841746542
Products in Payments
- TALZENNA (Drug) $128,233
- XTANDI (Drug) $40,635
- Xtandi (Drug) $39,432
- JEVTANA (Drug) $36,825
- LYNPARZA (Drug) $31,099
- Nubeqa (Drug) $26,634
- LYNPARZA (Biological) $23,235
- KEYTRUDA (Biological) $22,719
- Cabometyx (Drug) $18,503
- Bavencio (Drug) $16,905
- ILLUCCIX (Drug) $15,253
- ORGOVYX (Drug) $14,265
- CABOMETYX (Drug) $13,969
- Xofigo (Drug) $11,283
- Lenvima (Drug) $8,869
- FOTIVDA (Drug) $7,784
- BAVENCIO (Drug) $7,500
- OPDIVO (Biological) $6,633
- ERLEADA (Drug) $5,767
- PADCEV (Biological) $4,996
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New Orleans
Furhan Yunus, Md, MD
Hematology & Oncology — Payments: $156,701
Hematology & Oncology $156,701
Scott Sonnier, Md, MD
Hematology & Oncology — Payments: $20,534
Hematology & Oncology $20,534
David Morrison, Md, MD
Hematology & Oncology — Payments: $20,067
Hematology & Oncology $20,067
Sukanthini Subbiah, M.d, M.D
Hematology & Oncology — Payments: $12,772
Hematology & Oncology $12,772
Robert Veith, M.d, M.D
Hematology & Oncology — Payments: $12,408
Hematology & Oncology $12,408
Dr. Salvador Caputto, Md, MD
Hematology & Oncology — Payments: $9,385
Hematology & Oncology $9,385